



PRESS RELEASE

Alpha IVF inks IPO underwriting agreement with AmlInvestment Bank Berhad

- *Appoints AmlInvestment Bank Berhad as sole underwriter for IPO*
- *Listing on track for completion in first quarter of 2024*

Kuala Lumpur, Malaysia, 15 February 2024 - Fertility care specialist Alpha IVF Group Berhad (Alpha IVF, the Group, 阿儿法国际辅助生殖集团) signed an underwriting agreement with AmlInvestment Bank Berhad (AmlInvestment Bank) today, in conjunction with the upcoming initial public offering (IPO) of Alpha IVF on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Malaysia).

The IPO exercise entails a total of 1,458.0 million ordinary shares in Alpha IVF, comprising 364.5 million new shares and 1,093.5 million offer-for-sale shares. The total number of shares represents 30.0% of the enlarged share capital.

The IPO structure consists of an Institutional Offering of 1,239.3 million shares to institutional and selected investors, including 607.5 million shares to Bumiputera investors approved by the Ministry of Investment, Trade and Industry. Of the total institutional offering, 145.8 million are new shares.

The remaining 218.7 million new shares form the Retail Offering, which will be fully underwritten by AmlInvestment Bank. Out of the total retail offering, 194.4 million shares will be made available to the Malaysian public via balloting; and 24.3 million shares to eligible directors, eligible employees, and eligible persons who have contributed to the success of Alpha IVF.

Commenting on the signing of underwriting agreement, Dato' Dr Colin Lee Soon Soo (拿督李顺树医生), the Group Managing Director of Alpha IVF said, "The signing of the underwriting agreement is a significant milestone in our quest to join the league on the ACE Market of Bursa Malaysia. As we embark on this IPO, we are eager to tap the opportunities that afford us in the capital market.

Part of the IPO proceeds will help us execute our growth strategy of strengthening our operations in Malaysia, while also expanding our geographical reach to Indonesia, Cambodia or Laos, and China. This will lay the foundation for us to becoming a leading Assisted Reproductive Services (ARS) player in the region.

Against the backdrop of increasing infertility among young couples and delay in setting up families, we are encouraged that our expansion, both domestically and internationally, is ideally positioned to capitalise on these prospects."

Tracy Chen Wee Keng (陈惠琼), Chief Executive Officer of AmlInvestment Bank said, "AmlInvestment Bank is honoured to play a significant role in Alpha IVF Group Berhad's IPO which marks the largest ACE Market IPO listing on Bursa Malaysia. Alpha IVF has not only emerged as a renowned fertility centre in Malaysia and Singapore but has also taken a lead in shaping the ARS industry internationally. Their commitment to excellence is well-reflected in their outstanding clinical pregnancy success rates and unwavering dedication to innovative research and development in IVF techniques, surpassing industry standards and setting new benchmarks for excellence.



Alpha IVF has solidified its prestigious reputation regionally, well-positioning itself for further growth in the thriving ARS Industry. We believe the company is poised to take advantage of its next stage of expansion as it extends its presence in the domestic and international ARS markets.”

Barring unforeseen circumstances, Alpha IVF will be listed on the ACE Market of Bursa Malaysia in the first quarter of 2024. AmInvestment Bank is the principal adviser, sponsor, lead bookrunner, and sole underwriter for the Group’s IPO exercise.



Caption: From Left to Right

1. Dato’ Dr Colin Lee Soon Soo (拿督 李顺树医生), Group Managing Director of Alpha IVF Group Berhad
2. Tracy Chen Wee Keng (陈惠琼), Chief Executive Officer of AmInvestment Bank Berhad



About Alpha IVF Group Berhad (“Alpha IVF”)

Alpha IVF is a renowned fertility care specialist, currently operating in Malaysia and Singapore; Alpha IVF provides assisted reproductive services (ARS) with a primary focus on in-vitro fertilisation (IVF). The Group presently operates two specialist centres in Malaysia and one in Singapore: Alpha International Women Specialists Sdn Bhd (Alpha KL) in Selangor, Genesis Specialists Sdn Bhd (Genesis) in Penang, and Alpha International Women’s Specialists (Singapore) Pte Ltd (Alpha Singapore).

Besides IVF, Alpha IVF also provides other assisted reproductive procedures including intracytoplasmic sperm injection, intrauterine insemination, various diagnostics, testing and screening procedures, as well as cryopreservation of eggs, sperms and embryos.

Since inception in 2011, Alpha IVF has gained a strong reputation, with its brand name synonymous with exceptional success rates for Assisted Reproductive Services (ARS). The high pregnancy rates are attributed to Alpha IVF’s robust foundation of its “system of systems”, as well as its five strategic pillars, namely leading medical specialists, highly skilled embryologists, continuous research and development, innovative techniques, and cutting-edge laboratory and equipment.

The Group’s Malaysian operations have provided ARS to foreign patients from Indonesia, China, Singapore, Australia, and other countries. The Group has also innovated numerous treatments leading to improved pregnancy rates, and is actively involved in using artificial intelligence to enhance the IVF process.

**Issued for and on behalf of ALPHA IVF GROUP BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media enquiries, please contact:**

Ms. Azja Delana

azja@aquilas.com.my

T: 03-2711 1391/ 019-5886 088